P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

被引:26
|
作者
Thuault, S. [1 ,2 ]
Hayashi, S. [3 ]
Lagirand-Cantaloube, J. [1 ,2 ]
Plutoni, C. [1 ,2 ]
Comunale, F. [1 ,2 ]
Delattre, O. [4 ]
Relaix, F. [3 ]
Gauthier-Rouviere, C. [1 ,2 ]
机构
[1] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[2] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[3] INSERM UPMC AIM, UMRS787, Paris, France
[4] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France
关键词
P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch; TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION;
D O I
10.1038/onc.2012.217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012
引用
收藏
页码:1876 / 1887
页数:12
相关论文
共 50 条
  • [41] The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
    Bharathy, Narendra
    Berlow, Noah E.
    Wang, Eric
    Abraham, Jinu
    Settelmeyer, Teagan P.
    Hooper, Jody E.
    Svalina, Matthew N.
    Ishikawa, Yoshihiro
    Zientek, Keith
    Bajwa, Zia
    Goros, Martin W.
    Hernandez, Brian S.
    Wolff, Johannes E.
    Rudek, Michelle A.
    Xu, Linping
    Anders, Nicole M.
    Pal, Ranadip
    Harrold, Alexandria P.
    Davies, Angela M.
    Ashok, Arya
    Bushby, Darnell
    Mancini, Maria
    Noakes, Christopher
    Goodwin, Neal C.
    Ordentlich, Peter
    Keck, James
    Hawkins, Douglas S.
    Rudzinski, Erin R.
    Chatterjee, Bishwanath
    Bachinger, Hans Peter
    Barr, Frederic G.
    Liddle, Jennifer
    Garcia, Benjamin A.
    Mansoor, Atiya
    Perkins, Theodore J.
    Vakoc, Christopher R.
    Michalek, Joel E.
    Keller, Charles
    SCIENCE SIGNALING, 2018, 11 (557)
  • [42] MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
    Cassandri, Matteo
    Pomella, Silvia
    Rossetti, Alessandra
    Petragnano, Francesco
    Milazzo, Luisa
    Vulcano, Francesca
    Camero, Simona
    Codenotti, Silvia
    Cicchetti, Francesca
    Maggio, Roberto
    Festuccia, Claudio
    Gravina, Giovanni Luca
    Fanzani, Alessandro
    Megiorni, Francesca
    Catanoso, Marialuigia
    Marchese, Cinzia
    Tombolini, Vincenzo
    Locatelli, Franco
    Rota, Rossella
    Marampon, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [43] Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options
    Brown, Robert E.
    Buryanek, Jamie
    Katz, Amanda M.
    Paz, Keren
    Wolff, Johannes E.
    ONCOTARGET, 2016, 7 (29) : 46263 - 46272
  • [44] The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)
    Ciarapica, R.
    De Salvo, M.
    Carcarino, E.
    Bracaglia, G.
    Adesso, L.
    Leoncini, P. P.
    Dall'Agnese, A.
    Walters, Z. S.
    Verginelli, F.
    De Sio, L.
    Boldrini, R.
    Inserra, A.
    Bisogno, G.
    Rosolen, A.
    Alaggio, R.
    Ferrari, A.
    Collini, P.
    Locatelli, M.
    Stifani, S.
    Screpanti, I.
    Rutella, S.
    Yu, Q.
    Marquez, V. E.
    Shipley, J.
    Valente, S.
    Mai, A.
    Miele, L.
    Puri, P. L.
    Locatelli, F.
    Palacios, D.
    Rota, R.
    ONCOGENE, 2014, 33 (32) : 4173 - 4184
  • [45] TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma
    Gallo-Oller, Gabriel
    Pons, Guillem
    Sansa-Girona, Julia
    Navarro, Natalia
    Zarzosa, Patricia
    Garcia-Gilabert, Lia
    Cabre-Fernandez, Paula
    Burrieza, Gabriela Guillen
    Valero-Arrese, Lorena
    Segura, Miguel F.
    Lizcano, Jose M.
    de Toledo, Jose Sanchez
    Moreno, Lucas
    Gallego, Soledad
    Roma, Josep
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [46] The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)
    R Ciarapica
    M De Salvo
    E Carcarino
    G Bracaglia
    L Adesso
    P P Leoncini
    A Dall'Agnese
    Z S Walters
    F Verginelli
    L De Sio
    R Boldrini
    A Inserra
    G Bisogno
    A Rosolen
    R Alaggio
    A Ferrari
    P Collini
    M Locatelli
    S Stifani
    I Screpanti
    S Rutella
    Q Yu
    V E Marquez
    J Shipley
    S Valente
    A Mai
    L Miele
    P L Puri
    F Locatelli
    D Palacios
    R Rota
    Oncogene, 2014, 33 : 4173 - 4184
  • [47] TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma
    Gabriel Gallo-Oller
    Guillem Pons
    Júlia Sansa-Girona
    Natalia Navarro
    Patricia Zarzosa
    Lia García-Gilabert
    Paula Cabré-Fernandez
    Gabriela Guillén Burrieza
    Lorena Valero-Arrese
    Miguel F. Segura
    José M. Lizcano
    José Sánchez de Toledo
    Lucas Moreno
    Soledad Gallego
    Josep Roma
    Experimental Hematology & Oncology, 13
  • [48] Anlotinib destabilizes PAX3-FOXO1 to induce rhabdomyosarcoma cell death via upregulating NEK2
    Song, Zian
    Gong, Baocheng
    Qu, Tongyuan
    Chen, Yankun
    Zhao, Guangzong
    Jin, Yan
    Zhao, Qiang
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 177
  • [49] PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization
    Dumont, Sarah N.
    Lazar, Alexander J.
    Bridge, Julia A.
    Benjamin, Robert S.
    Trent, Jonathan C.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (02) : 213 - 220
  • [50] PAX3/7–FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization
    Sarah N. Dumont
    Alexander J. Lazar
    Julia A. Bridge
    Robert S. Benjamin
    Jonathan C. Trent
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 213 - 220